Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)
Authors' conclusion
Adrenal steroidogenesis inhibitors were the most commonly used medications amongst the centers. Despite the use of combination therapy, up to 25% of patients did not achieve disease control even in PTCOEs, highlighting the need for either more efficient combination therapies or novel therapeutic options.
Study context
- Population
- Patients with Cushing's disease (CD) under medical treatment at nine international Pituitary Tumors Centers of Excellence (PTCOEs), 2018–20209 PTCOEs
- Outcome
- Medical therapy use and biochemical control in CD
Methodological detailscross-sectional study, international, nine PTCOEs, 2018–2020
- Cross-sectional study
- International
- Nine PTCOEs
- 2018–2020
Main finding
As reported in the abstract
- Patients with CD receiving medical treatment, median % (range)
- 13.3% (4.8-82.9)
- Ketoconazole use (most frequent), median % of medically treated
- 26.5% (5-66.7)
- Metyrapone use, median %
- 17.2% (0-50)
- Pasireotide use, median %
- 9.3% (0-51.7)
- Cabergoline use, median %
- 2.8% (0-33.3)
- Osilodrostat use, median %
- 1.7% (0-25)
- Combination therapy, % of medically treated
- 13.6% (0-45.5)
- Mifepristone used in a single center, % of its medically treated patients
- 1.1%
- Median control rate with medical treatment
- 75% (10-100)
Observational data: associations, not effects.
Further findings
Center caseload
- Median active patients with CD per center
- 117 (35-279)
- Median new patients with CD annually
- 10 (4-42)
Original publication
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs). Pituitary. Published 29 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →